How Soon Can You Get COVID Again? Re-infection Explained

Reinfection with SARS-CoV-2 can happen within weeks of a previous infection, though most people retain enough immune protection to avoid it for at least a few months. Early in the pandemic, experts treated 90 days as a rough minimum window before reinfection was likely, but documented cases have occurred as early as 42 days after the first round of symptoms. What determines your personal timeline is a tangle of how much immunity you built, which variant you caught, whether you’re vaccinated, and what’s circulating when your antibodies start to fade.

The 90-Day Rule and Its Limits

During the first two years of the pandemic, public health guidance generally held that reinfection was uncommon within the first 90 days after symptoms appeared. Case reports supported this: in a review of healthcare worker reinfections, the shortest documented gap between symptom onsets was about 42 days, while other cases showed intervals of 94 days and roughly four months.¹ That 90-day figure was never a guarantee of safety. It was a statistical observation: most people who had recently recovered didn’t test positive again in that window. Once new variants, especially Omicron, entered the picture, even that rough guideline became less reliable.

The reason the early post-infection period offers some protection is straightforward. Your immune system mounts an aggressive response during an active infection, and for the weeks that follow, antibody levels are high and immune cells are on alert. A large Texas-based survey tracking over 4,500 participants found that antibody levels rose robustly for about 100 days after infection before beginning to plateau and eventually decline, with the speed of that decline depending on factors like age, body mass, smoking habits, and how sick you got the first time.² So the 90-day mark roughly aligns with peak antibody levels. After that, the window of heightened vulnerability starts opening gradually.

Why Immunity Fades but Doesn’t Disappear

Antibodies are the first line of defense against reinfection, and they’re also the part of immunity that wanes most visibly. But they’re not the whole story. Your immune system also builds memory T cells, which are slower to act than antibodies but play a critical role in controlling an infection once it starts. Research has shown that durable T cell memory from either infection or vaccination can help protect against severe disease for more than 14 months, even as protection against catching the virus again wanes over time.³ Memory CD8+ T cells, sometimes called killer T cells, are especially useful here because they tend to target highly conserved parts of the virus that don’t change much from variant to variant, allowing them to recognize new strains even when antibodies struggle to.⁴

This distinction matters for understanding what “getting COVID again” actually looks like. Your antibodies might not prevent the virus from gaining a foothold in your nose and throat, which means you can test positive and feel sick. But your T cells often kick in quickly enough to keep the infection from reaching your lungs or causing the kind of dangerous immune overreaction that leads to hospitalization. Long-lived memory T cells appear to stabilize over time and remain functional even when the virus mutates, which is why researchers believe most people retain protection against severe outcomes well beyond the point where reinfection becomes possible.⁵

There’s also a mucosal layer to immunity that researchers are still working to understand. Nasal IgA antibodies, which line the surfaces of your airways, appear to be particularly important for blocking infection right at the point of entry. Studies have found that reinfection boosts these mucosal antibodies more effectively than vaccination does, suggesting that each encounter with the actual virus trains your local defenses a bit better.⁶ Children, interestingly, start with lower nasal IgA levels against coronaviruses than adults, which may partly explain why their reinfection patterns differ.

How Variants Rewrote the Timeline

If there’s one factor that made reinfection go from rare to routine, it was the arrival of Omicron in late 2021. Before Omicron, reinfection rates were genuinely low. One study comparing variants found reinfection in less than half a percent of people infected during the Alpha wave, about 1.2% during Delta, and a striking 13% during Omicron, making it roughly 30 times more common than in the Alpha period.⁷ Another cohort tracked people who had recovered from COVID in the pandemic’s first year and found that reinfection incidence jumped from about 2.7% in the pre-Omicron era to nearly 22% during the Omicron wave, with the vast majority of those reinfections producing symptoms.⁸

The reason is partly a concept called antigenic drift: the virus’s surface proteins change enough over time that antibodies trained on an older version don’t bind as effectively to the new one. This process can substantially limit how long immunity from a previous infection or vaccination actually holds up.⁹ Omicron didn’t just drift; it leaped. Its spike protein was so different from earlier variants that prior immunity, whether from infection or vaccination, offered far less protection against catching it than it had against Delta or Alpha.

A major UK study following roughly 45,000 reinfections during successive Omicron sub-waves found that protection against reinfection was consistently higher when your most recent infection had been with a more recent variant. Protection also waned over time from the most recent infection if that infection had been within the past year, but it actually held steady or slightly increased when the most recent infection was with a variant from over a year earlier. This somewhat counterintuitive pattern likely reflects the complex interplay of immune imprinting, where the sequence of infections and vaccinations you’ve had shapes how your immune system responds to the next encounter.¹⁰

How Much Does Vaccination Help?

People with “hybrid immunity,” meaning they’ve both been infected and vaccinated, consistently take longer to get reinfected than those relying on natural immunity alone. One study found the median time to reinfection was about 391 days for people with hybrid immunity compared to 294 days for those with only prior infection.¹¹ A large Swedish study put harder numbers on the effect: two doses of vaccine on top of a prior infection cut the risk of reinfection by about two-thirds compared to natural immunity alone, and that protection held without significant weakening for up to nine months.¹²

Booster doses work too, but their protection against infection (as opposed to severe illness) fades faster. One population-based cohort study found booster effectiveness against infection started at around 61% in the first month but declined to roughly 16% by the sixth month.¹³ Updated bivalent vaccines targeting Omicron subvariants did show improved neutralizing activity against circulating strains, regardless of a person’s prior infection history.¹⁴ The practical takeaway is that vaccination extends the gap between infections and makes each one less dangerous, but no vaccine strategy currently available prevents reinfection indefinitely.

Is a Second Infection Milder Than the First?

The answer here is mostly yes, but with caveats. A systematic review and meta-analysis pooling data across multiple studies found no overall significant difference in clinical patterns or severity between first infections and reinfections.¹⁵ That might sound alarming, but it’s averaging across a wide mix of study designs and time periods. When researchers zoom in more carefully, reinfections often do appear milder. A Korean study found that severity during reinfection was lower than the first infection overall, and people who had been vaccinated within 91 days of reinfection showed an even more attenuated course.¹⁶

One important exception: a study from early in the pandemic found that hospitalization was actually more common during suspected reinfection than during initial infection, at roughly 11% versus 5%.¹⁷ The likely explanation is selection bias: people who got reinfected in the earlier waves were often older or had underlying conditions that put them at higher risk in the first place. The broader evidence, particularly from the Omicron era when reinfections became widespread across all demographics, leans toward reinfections being less severe on average, especially in vaccinated individuals.

Reinfection and Long COVID

Whether reinfection increases your risk of long COVID is one of the more contested questions in the field right now. A UK community-based cohort study found that long COVID was actually less common after a second infection than after a first: about 4% of adults reported it after their first infection versus 2.4% after a second.¹⁸ For children under 16, the rates were lower still, around 1% after a first infection and 0.6% after a second.

A more recent preprint analysis, however, reached the opposite conclusion. Using a matched comparison approach, it found that reinfection carried a roughly 35% higher risk of developing long COVID compared to a similar first infection.¹⁹ The discrepancy between these findings likely reflects differences in methodology, time periods studied, and how long COVID was defined. The honest answer is that the science isn’t settled. What is clear is that every infection carries some non-zero risk of persistent symptoms, so fewer infections generally means lower cumulative risk.

Children and Reinfection

Kids can and do get reinfected, though less frequently than adults and with generally milder outcomes. A large Serbian study tracking over 32,000 children and adolescents with COVID found that about 3% experienced a documented reinfection. The cumulative reinfection risk climbed over time: 1.3% at six months, 4% at one year, and nearly 8% by 21 months. Reassuringly, severe disease was about five times less likely during reinfection than during the first infection, hospitalizations dropped from 1.3% to 0.5%, and no reinfected child in the cohort died.²⁰ The vast majority of these reinfections were recorded in 2022, when Omicron was dominant, underscoring how much the variant landscape drives reinfection rates in all age groups.

Rebound Versus Reinfection

A common source of confusion is when symptoms return shortly after recovering, especially if someone took an antiviral like Paxlovid. This is usually rebound, not reinfection. Rebound means the virus was never fully cleared and flared back up, often within a week or two. One study found that about 3.5% of Paxlovid-treated patients experienced a rebound of infection within seven days, rising to about 5.4% within 30 days.²¹ Molnupiravir showed similar rates. Rebound is frustrating, but it’s a different phenomenon from true reinfection, which involves catching the virus anew from a separate exposure.

Distinguishing the two can be tricky in practice. Researchers have outlined criteria for confirming true reinfection: ideally, you’d want complete viral genome sequencing from both episodes showing two different viral strains, evidence that the virus in the second episode was actually capable of replicating, and comparison of the immune response between the two episodes. A longer gap between episodes makes reinfection more plausible; a shorter gap, especially within the first few weeks, points toward rebound or lingering viral shedding.²² In everyday life, most people don’t have access to genomic sequencing, so the distinction often comes down to timing and clinical context.

Population-Level Reinfection Rates Over Time

Across the pandemic as a whole, a meta-analysis encompassing over 14 million people across 55 studies estimated the overall reinfection rate at just under 1%, though individual study rates ranged from 0% to over 28% depending on the population, the time frame, and which variants were circulating.²³ That low overall number is heavily weighted by the pre-Omicron era, when reinfections were genuinely rare. An Italian population-level study following over a million people found a reinfection rate of about 6 per 1,000 among previously infected individuals up through early 2022, with the rate not climbing much even 18 to 22 months out, suggesting natural immunity’s protection against reinfection lasted beyond a year for many people even before Omicron reshaped the landscape.²⁴

During the Omicron sub-waves, numbers climbed sharply. The UK COVID-19 Infection Survey tracked reinfection percentages rising with each successive wave: about 10% during BA.1, 11% during BA.2, 14% during BA.4/5, and 16% during the BQ.1/XBB.1.5 wave.¹⁰ Each new sub-variant eroded the protection left by the last, even when the interval between infections was relatively short.

Can You Spread COVID During a Reinfection?

Yes. Reinfection cases can carry infectious virus, particularly in the nasal cavity. Researchers have noted that some reinfection cases showed low cycle threshold values on PCR testing, indicating high viral loads that could readily be transmitted to others.²⁵ The practical implication is that even if your second bout feels milder, you’re still capable of passing the virus along to someone more vulnerable. This was one of the early warnings against relying on natural herd immunity: reinfections mean the population never reaches a point where the virus simply can’t spread.

COVID as a Recurring Infection

Modeling work using classic epidemiological frameworks has suggested that SARS-CoV-2, particularly the Omicron lineage, is settling into an oscillating endemic pattern in which immunity wanes, infections rise, population immunity rebuilds, and cases drop again, much like seasonal flu. Mathematical models indicate that continuous vaccination programs alone aren’t enough to escape these recurring infection waves.²⁶ For individuals, this means the question isn’t really whether you’ll encounter the virus again but when, and the best strategy is making sure each encounter finds your immune system as well-prepared as possible through timely boosters and general health maintenance. The virus is behaving more like something people catch every year or two, with each round shaped by the evolving interplay between the virus’s mutations and the population’s accumulated immunity.